keyword
MENU ▼
Read by QxMD icon Read
search

treatment of hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/29454098/quantitative-imaging-features-and-postoperative-hepatic-insufficiency-a-multi-institutional-expanded-cohort
#1
Linda M Pak, Jayasree Chakraborty, Mithat Gonen, William C Chapman, Richard Kg Do, Bas Groot Koerkamp, Kees Verhoef, Ser Yee Lee, Marco Massani, Eric P van der Stok, Amber L Simpson
BACKGROUND: Post-hepatectomy liver insufficiency (PHLI) is a significant cause of morbidity and mortality after liver resection. Quantitative imaging analysis using CT scans measures variations in pixel intensity related to perfusion. A preliminary study demonstrated a correlation between quantitative imaging features of the future liver remnant (FLR) parenchyma from preoperative CT scans and PHLI. The objective of the present study was to explore the potential application of quantitative imaging analysis in PHLI in an expanded, multi-institutional cohort...
February 14, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29454068/o-glcnacylation-of-rack1-promotes-hepatocellular-carcinogenesis
#2
Fangfang Duan, Hao Wu, Dongwei Jia, Weicheng Wu, Shifang Ren, Lan Wang, Shushu Song, Xinying Guo, Fenglin Liu, Yuanyuan Ruan, Jianxin Gu
BACKGROUND & AIMS: Aberrant oncogenic mRNA translation and protein O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) are general features during tumorigenesis. Nevertheless, whether and how these two pathways are interlinked remain unknown. Our previous study indicated that ribosomal RACK1 promoted the chemoresistance and growth in hepatocellular carcinoma (HCC). The aim of this study is to examine the role of RACK1 O-GlcNAcylation in oncogene translation and HCC carcinogenesis...
February 14, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29453759/systemic-treatment-of-patients-with-advanced-unresectable-hepatocellular-carcinoma-emergence-of-therapies
#3
REVIEW
Weijing Sun, Roniel Cabrera
To date, sorafenib, a multiple tyrosine kinase inhibitor, is the only systemic agent approved by the FDA in the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Several other tyrosine kinase-inhibiting agents have been investigated in the first-line setting, either alone (sunitinib, brivanib, linifanib, and lenvatinib) or in combination with sorafenib (erlotinib and doxorubicin) in phase 3 trials. However, none of these studies demonstrated an improvement in survival over sorafenib...
February 17, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29453098/control-of-viral-transcripts-as-a-concept-for-future-hbv-therapies
#4
REVIEW
Christoph Seeger
Chronic hepatitis B virus infections affect over 250 million people world-wide, and, at present, are not curable. Of those, over 800000 are expected to die yearly from complications including cirrhosis and primary hepatocellular carcinoma (HCC). A viral episomal DNA intermediate, covalently closed circular DNA (cccDNA) can persist in nuclei of infected hepatocytes and trigger production of infectious virus. Current standard of care treatments against chronic HBV infections primarily rely on nucleoside analogs (NA) that inhibit de novo virus production by inhibiting the viral reverse transcriptase and, as a consequence, reducing virus titers...
February 13, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29452863/chest-wall-toxicity-after-hypofractionated-proton-beam-therapy-for-liver-malignancies
#5
Rosanna Yeung, Stephen R Bowen, Tobias R Chapman, Grayden T MacLennan, Smith Apisarnthanarax
PURPOSE: Normal liver-sparing with proton beam therapy (PBT) allows for dose escalation in the treatment of liver malignancies, but it may result in high doses to the chest wall (CW). CW toxicity (CWT) data after PBT for liver malignancies are limited, with most published reports describing toxicity after a combination of hypofractionated proton and photon radiation therapy. We examined the incidence and associated factors for CWT after hypofractionated PBT for liver malignancies. METHODS AND MATERIALS: We retrospectively reviewed the charts of 37 consecutive patients with liver malignancies (30 hepatocellular carcinoma, 6 intrahepatic cholangiocarcinoma, and 1 metastasis) treated with hypofractionated PBT...
December 24, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29452700/liver-resection-for-recurrent-hepatocellular-carcinoma-to-improve-survivability-a-proposal-of-indication-criteria
#6
Rempei Yagi, Yutaka Midorikawa, Masamichi Moriguchi, Hisashi Nakayama, Osamu Aramaki, Shintaro Yamazaki, Tokio Higaki, Tadatoshi Takayama
BACKGROUND: Despite curative resection of hepatocellular carcinoma, patients have a high probability of recurrence. We examined indications for liver resection in cases of recurrent hepatocellular carcinoma. METHODS: Patients undergoing a second liver resection (n =210) or treatment by transcatheter arterial chemoembolization (n =184) for recurrent hepatocellular carcinoma of up to 3 lesions were included. We developed a prediction score based on prognostic factors and compared survival according to this prediction score...
February 14, 2018: Surgery
https://www.readbyqxmd.com/read/29451521/-personalized-healthcare-in-hepatocellular-carcinoma-multi-society-italian-position-paper
#7
Franco Trevisani, Francesca Garuti, Andrea Neri
Hepatocellular carcinoma (HCC) is a neoplasm characterized by both clinical and biological heterogeneity. Its management requires the expertise of multiple medical specialists and is made complex by the old age of most patients, frequently showing comorbidities. Therefore, HCC management needs a multidisciplinary approach. The aim of this article is to illustrate multi-society recommendations regarding the management of HCC patients, from diagnosis to treatment and follow-up. In particular, in every stage, HCC treatment comprises multiple alternatives and the best option for every patient should be decided by a multidisciplinary team...
January 2018: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/29450751/left-lobe-mobilization-strategy-of-right-sided-major-hepatectomy-for-treatment-of-a-tumor-causing-severe-inferior-vena-cava-compression-a-novel-strategy-using-the-modified-liver-hanging-maneuver
#8
Kenichiro Araki, Norio Kubo, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Hiroyuki Kuwano, Ken Shirabe
BACKGROUND: Massive bleeding during major hepatectomy is associated with greater mortality and morbidity.1 Our previous study shows that inferior vena cava (IVC) compression by tumor and an anterior approach without the liver-hanging maneuver (LHM) are risk factors for massive bleeding.2 The LHM is useful for controlling bleeding in deeper parenchymal transection planes.3 However, severe compression of the IVC by tumor makes it difficult to insert a hanging tape.4 The study shows a novel modified LHM strategy for severe IVC compression to minimize intraoperative bleeding...
February 14, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29450606/combination-transarterial-chemoembolization-and-microwave-ablation-improves-local-tumor-control-for-3-to-5-cm-hepatocellular-carcinoma-when-compared-with-transarterial-chemoembolization-alone
#9
Amanda R Smolock, Mircea M Cristescu, Audrey Hinshaw, Kaitlin M Woo, Shane A Wells, Timothy J Ziemlewicz, Meghan G Lubner, Prasad S Dalvie, J Louis Hinshaw, Christopher L Brace, Orhan S Ozkan, Fred T Lee, Paul Laeseke
PURPOSE: To compare transarterial chemoembolization (TACE) monotherapy to combination TACE and microwave ablation (MWA) for local control of 3- to 5-cm hepatocellular carcinoma (HCC). METHODS: Patients with HCC between 3 and 5 cm treated with TACE monotherapy or combination TACE + MWA at a single institution between 2007 and 2016 were retrospectively reviewed. Twenty-four HCCs (median diameter 3.8 cm) in 16 patients (13 males; median age 64 years) were treated using TACE monotherapy...
February 15, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29449645/egfr-pi3k-pdk1-pathway-regulates-yap-signaling-in-hepatocellular-carcinoma-the-mechanism-and-its-implications-in-targeted-therapy
#10
Hongwei Xia, Xinyu Dai, Huangfei Yu, Sheng Zhou, Zhenghai Fan, Guoqing Wei, Qiulin Tang, Qiyong Gong, Feng Bi
The epidermal growth factor receptor (EGFR) pathway and Hippo signaling play an important role in the carcinogenesis of hepatocellular carcinoma (HCC). However, the crosstalk between these two pathways and its implications in targeted therapy remains unclear. We found that the activated EGFR signaling could bypass RhoA to promote the expression of YAP(Yes-associated protein), the core effector of the Hippo signaling, and its downstream target Cyr61. Further studies indicated that EGFR signaling mainly acted through the PI3K-PDK1 (Phosphoinositide 3-kinase-Phosphoinositide-dependent kinase-1) pathway to activate YAP, but not the AKT and MAPK pathways...
February 15, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29448306/albi-versus-child-pugh-grading-systems-for-liver-function-in-patients-with-hepatocellular-carcinoma
#11
Seong K Na, Sun Y Yim, Sang J Suh, Young K Jung, Ji H Kim, Yeon S Seo, Hyung J Yim, Jong E Yeon, Kwan S Byun, Soon H Um
BACKGROUND: The prognostic performance of the albumin-bilirubin (ALBI) grade in hepatocellular carcinoma (HCC) as an objective method of assessing liver function was investigated. METHODS: Data from 2099 patients with HCC in Korea were collected and analyzed retrospectively. The discriminative performance of ALBI grade was compared with Child-Pugh (C-P) grade for different stages or treatments. RESULTS: The median follow up duration was 16...
February 15, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29446324/hepatocellular-carcinoma-surveillance-with-ultrasound-cost-effectiveness-high-risk-populations-uptake
#12
Maxime Ronot, Romain Pommier, Marco Dioguardi Burgio, Yvonne Purcell, Pierre Nahon, Valérie Vilgrain
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second cause of cancer-related deaths worldwide. In most cases, it is diagnosed in patients with identified risk factors, mainly cirrhosis from all causes. These patients are candidates for a surveillance program that, depending on guidelines, involves regular liver ultrasound alone or combined with serum markers. These programs have been shown to improve the oncological outcome by detecting earlier stage tumors and providing patients with potentially curative treatment and improved survival...
February 15, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29445150/loss-of-ndrg2-in-liver-microenvironment-inhibits-cancer-liver-metastasis-by-regulating-tumor-associate-macrophages-polarization
#13
Mengyang Li, Xiaofeng Lai, Ying Zhao, Yuan Zhang, Minghui Li, Danxiu Li, Jing Kong, Yong Zhang, Pengyu Jing, Huichen Li, Hongyan Qin, Liangliang Shen, Libo Yao, Jipeng Li, Kefeng Dou, Jian Zhang
The liver is the predominant metastatic site for several types of malignancies. Tumor-associated macrophages (TAMs) in the liver play crucial roles in the metastasis process. Shifting tumor-promoting M2-like TAMs toward the M1-like phenotype, which exerts tumor suppressor functions via phagocytosis and the secretion of inhibitory factors, may be a potential therapeutic strategy for liver cancer metastasis treatment.We first cloned NDRG2 (N-myc downstream-regulated gene 2) and verified its tumor suppressor role in multiple solid tumors, including colorectal cancer and hepatocellular carcinoma...
February 14, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29444653/transarterial-chemoembolization-tace-using-mitomycin-and-lipiodol-with-or-without-degradable-starch-microspheres-for-hepatocellular-carcinoma-comparative-study
#14
Tatjana Gruber-Rouh, Cornelia Schmitt, Nagy N N Naguib, N A Nour-Eldin, Katrin Eichler, Martin Beeres, Thomas J Vogl
BACKGROUND: To evaluate survival data and local tumor control after transarterial chemoembolization in two groups with different embolization protocols for the treatment of HCC patients. METHODS: Ninty-nine patients (mean age: 63.6 years), 78 male (78.8%) with HCC were repeatedly treated with chemoembolization in 4-week-intervals. Eighty-eight patients had BCLC-Stage-B and in 11 patients, chemoembolization was performed for bridging (BCLC-Stage-A). In total, 667 chemoembolization treatments were performed (mean 6...
February 14, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29444164/evolution-of-nodule-stiffness-might-predict-response-to-local-ablative-therapy-a-series-of-patients-with-hepatocellular-carcinoma
#15
Michael Praktiknjo, Viktoria Krabbe, Alessandra Pohlmann, Matthias Sampels, Christian Jansen, Carsten Meyer, Christian P Strassburg, Jonel Trebicka, Maria A Gonzalez Carmona
BACKGROUND: Early information on treatment response of HCC to local ablative therapy is crucial. Elastography as a non-invasive method has recently been shown to play a potential role in distinguishing between benign and malignant liver lesions. Elastography of hepatocellular carcinoma (HCC) in early response to local ablative therapy has not been studied to date. METHODS: We prospectively included a cohort of 14 patients with diagnosis of HCC who were treated with local ablative therapy (transarterial chemoembolization, TACE and/or radiofrequency ablation, RFA)...
2018: PloS One
https://www.readbyqxmd.com/read/29442276/novel-albumin-bilirubin-grade-based-risk-prediction-model-for-patients-with-hepatocellular-carcinoma-undergoing-chemoembolization
#16
Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
BACKGROUND: Recently, albumin-bilirubin (ALBI) grade has been suggested as a better surrogate for hepatic functional reserve for patients with hepatocellular carcinoma (HCC). AIMS: We developed and validated a novel prediction model to predict outcome for HCC patients who underwent transcatheter arterial chemoembolization (TACE) as a first-line therapy. METHODS: From a multivariate Cox regression model for overall survival, five objective variables (ALBI grade), the Barcelona clinic liver cancer (BCLC) stage, response after the first TACE session, Alpha-fetoprotein level, and sex were chosen and the ABRAS score was developed from the derivation cohort (n = 476) and scored to generate an 8-point risk prediction model...
February 13, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29442042/trim59-promotes-cell-proliferation-migration-and-invasion-in-human-hepatocellular-carcinoma-cells
#17
Gang Sun, Xin Sui, Dayue Han, Jianjun Gao, Yining Liu, Lin Zhou
The human tripartite motif (TRIM) 59 has been implicated in tumorigenesis of many types of cancer. However, the biological function and molecular mechanism of TRIM59 in hepatocellular carcinoma (HCC) remains unknown. In our study, the purpose was to investigate the impact of TRIM59 on the biologic behavior of HCC cells. We observed that TRIM59 was highly expressed in HCC cells compared with a normal human hepatocyte cell line. Lentivirus-mediated knocking down of TRIM59 significantly suppressed the proliferation, migration and invasion of HCC cells, whereas overexpression of TRIM59 enhanced cell growth and metastasis...
November 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29441336/a-prospective-randomized-study-comparing-radiofrequency-ablation-and-hepatic-resection-for-hepatocellular-carcinoma
#18
Hae Won Lee, Jeong Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Joong-Won Park, Sang-Jae Park, Seong Hoon Kim, Nam-Joon Yi, Kyung-Suk Suh
Purpose: Although there are several prospective clinical studies comparing radiofrequency ablation (RFA) and hepatic resection (HR) for the treatment of hepatocellular carcinoma, there are few trials that have been performed in strictly homogeneous patients. Methods: Patients who were newly diagnosed with a solitary hepatocellular carcinoma were randomized to the HR or RFA group. Inclusion criteria were as follows: age ≥ 20 years but ≤ 70 years, Child-Pugh class A, maximal diameter of the tumor ≥ 2 cm but ≤ 4 cm, no previous treatment history, and platelet count > 80,000/mm 3 ...
February 2018: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/29440463/immune-activation-underlies-a-sustained-clinical-response-to-yttrium-90-radioembolisation-in-hepatocellular-carcinoma
#19
Valerie Chew, Yun Hua Lee, Lu Pan, Nurul J M Nasir, Chun Jye Lim, Camillus Chua, Liyun Lai, Sharifah Nur Hazirah, Tony Kiat Hon Lim, Brian K P Goh, Alexander Chung, Richard H G Lo, David Ng, Rene L F Filarca, Salvatore Albani, Pierce K H Chow
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. DESIGN: Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE...
February 13, 2018: Gut
https://www.readbyqxmd.com/read/29439719/myl6b-a-myosin-light-chain-promotes-mdm2-mediated-p53-degradation-and-drives-hcc-development
#20
Xingwang Xie, Xueyan Wang, Weijia Liao, Ran Fei, Nan Wu, Xu Cong, Qian Chen, Lai Wei, Yu Wang, Hongsong Chen
BACKGROUND: Identification of novel MDM2 or p53 binding proteins may reveal undefined oncogenes, tumor suppressors, signaling pathways and possible treatment targets. METHODS: By means of immunoprecipitation and Mass Spectrometry analysis, we aimed to identify novel regulators of the MDM2-p53 pathway. We further clarified the impact of MYL6B on the p53 protein level and on the process of apoptosis. We also investigated the role of MYL6B in hepatocellular carcinoma by clone formation assay and by determining the correlation between its expression and prognosis of HCC patients...
February 13, 2018: Journal of Experimental & Clinical Cancer Research: CR
keyword
keyword
40124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"